Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods (2016 - 2025)

Ocular Therapeutix (OCUL) has 12 years of Finished Goods data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Finished Goods rose 22.74% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 22.74%, while the annual FY2025 figure was $1.6 million, 22.74% up from the prior year.
  • Finished Goods reached $1.6 million in Q4 2025 per OCUL's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Finished Goods topped out at $1.9 million in Q3 2025 and bottomed at $257000.0 in Q4 2021.
  • Average Finished Goods over 5 years is $917900.0, with a median of $1.0 million recorded in 2023.
  • Peak YoY movement for Finished Goods: plummeted 61.26% in 2021, then surged 198.05% in 2022.
  • A 5-year view of Finished Goods shows it stood at $257000.0 in 2021, then soared by 198.05% to $766000.0 in 2022, then increased by 29.37% to $991000.0 in 2023, then soared by 34.91% to $1.3 million in 2024, then increased by 22.74% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $1.6 million in Q4 2025, $1.9 million in Q3 2025, and $1.1 million in Q2 2025.